4-Cyanamidobenzenesulfonamide derivatives: a novel class of human and bacterial carbonic anhydrase inhibitors

References

• (a) Scott KA, Njardarson JT. Analysis of US FDA-approved drugs containing sulfur atoms. Top Curr Chem. 2018;376(1):5;
   PubMed Web of Science ®Google Scholar
  (b) Carta F, Supuran CT, Scozzafava A. Sulfonamides and their isosters as carbonic anhydrase inhibitors. Future Med Chem. 2014;6(10):1149–1165;
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors? J Enzyme Inhib Med Chem. 2018;33(1):485–495.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7(2):168–181;
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci. 2021;135(10):1233–1249;
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Novel carbonic anhydrase inhibitors. Future Med Chem. 2021;13(22):1935–1937.
   PubMed Web of Science ®Google Scholar
• (a) Aspatwar A, Tolvanen MEE, Barker H, Syrjänen L, Valanne S, Purmonen S, Waheed A, Sly WS, Parkkila S. Carbonic anhydrases in metazoan model organisms: molecules, mechanisms, and physiology. Physiol Rev. 2022;102(3):1327–1383;
   PubMed Web of Science ®Google Scholar
  (b) Aspatwar A, Syrjänen L, Parkkila S. Roles of carbonic anhydrases and carbonic anhydrase related proteins in Zebrafish. IJMS. 2022;23(8):4342.
   Google Scholar
• (a) Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev. 2020;40(6):2485–2565;
   PubMed Web of Science ®Google Scholar
  (b) Alterio V, Di Fiore A, D'Ambrosio K, Supuran CT, De Simone G. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112(8):4421–4468;
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2017;12(1):61–88.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31(3):345–360;
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Carbonic anhydrases as drug targets-an overview. Curr Top Med Chem. 2007;7(9):825–833;
   PubMed Web of Science ®Google Scholar
  (c) Nocentini A, Angeli A, Carta F, Winum J-Y, Zalubovskis R, Carradori S, Capasso C, Donald WA, Supuran CT. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem. 2021;36(1):561–580.
   PubMed Web of Science ®Google Scholar
• (a) Angeli A, Carta F, Nocentini A, Winum J-Y, Zalubovskis R, Akdemir A, Onnis V, Eldehna WM, Capasso C, Simone GD, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites. 2020;10(10):412;
   PubMed Web of Science ®Google Scholar
  (b) Angeli A, Carta F, Nocentini A, Winum J-Y, Zalubovskis R, Onnis V, Eldehna WM, Capasso C, Carradori S, Donald WA, et al. Response to perspectives on the classical enzyme carbonic anhydrase and the search for inhibitors. Biophys J. 2021;120(1):178–181;
   PubMed Web of Science ®Google Scholar
  (c) McDonald PC, Chafe SC, Supuran CT, Dedhar S. Cancer therapeutic targeting of hypoxia induced carbonic anhydrase IX: from bench to bedside. Cancers (Basel). 2022;14(14):3297;
   PubMed Web of Science ®Google Scholar
  (d) Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2018;27(12):963–970.
   PubMed Web of Science ®Google Scholar
• (a) Nerella SG, Singh P, Arifuddin M, Supuran CT. Anticancer carbonic anhydrase inhibitors: a patent and literature update 2018-2022. Expert Opin Ther Pat. 2022;32(8):833–847;
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2021;30(12):1197–1208;
   PubMed Web of Science ®Google Scholar
  (c) Mincione F, Nocentini A, Supuran CT. Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opin Drug Discov. 2021;16(10):1209–1225;
   PubMed Web of Science ®Google Scholar
  (d) Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov. 2020;15(6):671–686.
   PubMed Web of Science ®Google Scholar
• (a) Amedei A, Capasso C, Nannini G, Supuran CT. Microbiota, bacterial carbonic anhydrases, and modulators of their activity: links to human diseases? Mediators Inflamm. 2021;2021:6926082;
   PubMedGoogle Scholar
  (b) Nocentini A, Supuran CT, Capasso C. An overview on the recently discovered iota-carbonic anhydrases. J Enzyme Inhib Med Chem. 2021;36(1):1988–1995;
   PubMed Web of Science ®Google Scholar
  (c) Campestre C, De Luca V, Carradori S, Grande R, Carginale V, Scaloni A, Supuran CT, Capasso C. Carbonic anhydrases: new perspectives on protein functional role and inhibition in Helicobacter pylori. Front Microbiol. 2021; 12:629163;
   PubMed Web of Science ®Google Scholar
  (d) Del Prete S, Nocentini A, Supuran CT, Capasso C. Bacterial ι-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem. 2020;35(1):1060–1068.
   PubMed Web of Science ®Google Scholar
• (a) De Luca V, Carginale V, Supuran CT, Capasso C. The gram-negative bacterium Escherichia coli as a model for testing the effect of carbonic anhydrase inhibition on bacterial growth. J Enzyme Inhib Med Chem. 2022;37(1):2092–2098;
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT, Capasso C. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat. 2020;30(12):963–982;
   PubMed Web of Science ®Google Scholar
  (c) Giovannuzzi S, Hewitt CS, Nocentini A, Capasso C, Costantino G, Flaherty DP, Supuran CT. Inhibition studies of bacterial α-carbonic anhydrases with phenols. J Enzyme Inhib Med Chem. 2022;37(1):666–671.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat. 2018;28(10):745–754;
   PubMed Web of Science ®Google Scholar
  (b) Flaherty DP, Seleem MN, Supuran CT. Bacterial carbonic anhydrases: underexploited antibacterial therapeutic targets. Future Med Chem. 2021;13(19):1619–1622;
   PubMed Web of Science ®Google Scholar
  (c) Hewitt CS, Abutaleb NS, Elhassanny AEM, Nocentini A, Cao X, Amos DP, Youse MS, Holly KJ, Marapaka AK, An W, et al. Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against Neisseria gonorrhoeae. ACS Infect Dis. 2021;7(7):1969–1984;
   PubMed Web of Science ®Google Scholar
  (d) Abutaleb NS, Elhassanny AEM, Nocentini A, Hewitt CS, Elkashif A, Cooper BR, Supuran CT, Seleem MN, Flaherty DP. Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae. J Enzyme Inhib Med Chem. 2022;37(1):51–61;
   PubMed Web of Science ®Google Scholar
  (e) An W, Holly KJ, Nocentini A, Imhoff RD, Hewitt CS, Abutaleb NS, Cao X, Seleem MN, Supuran CT, Flaherty DP, et al. Structure-activity relationship studies for inhibitors for vancomycin-resistant Enterococcus and human carbonic anhydrases. J Enzyme Inhib Med Chem. 2022;37(1):1838–1844.
   PubMed Web of Science ®Google Scholar
• (a) Capasso C, Supuran CT. Sulfa and trimethoprim-like drugs - antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors. J Enzyme Inhib Med Chem. 2014;29(3):379–387;
   PubMed Web of Science ®Google Scholar
  (b) Capasso C, Supuran CT. Anti-infective carbonic anhydrase inhibitors: a patent and literature review. Expert Opin Ther Pat. 2013;23(6):693–704;
   PubMed Web of Science ®Google Scholar
  (c) Nishimori I, Vullo D, Minakuchi T, Scozzafava A, Osman SM, AlOthman Z, Capasso C, Supuran CT. Anion inhibition studies of two new β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila. Bioorg Med Chem Lett. 2014;24(4):1127–1132;
   PubMed Web of Science ®Google Scholar
  (d) Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem. 2015;30(2):325–332;
   PubMed Web of Science ®Google Scholar
  (e) Ferraroni M, Del Prete S, Vullo D, Capasso C, Supuran CT. Crystal structure and kinetic studies of a tetrameric type II β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. Acta Crystallogr D Biol Crystallogr. 2015;71(Pt 12):2449–2456.
   PubMedGoogle Scholar
• (a) Brogden RN, Heel RC, Speight TM, Avery GS. Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs. 1978;15(2):93–131;
   PubMed Web of Science ®Google Scholar
  (b) Winship DH. Cimetidine in the treatment of duodenal ulcer: review and commentary. Gastroenterology. 1978;74(2 Pt 2):402–406.
   PubMed Web of Science ®Google Scholar
• Yoo SE, Yi KY, Lee S, Suh J, Kim N, Lee BH, Seo HW, Kim SO, Lee DH, Lim H, et al. A novel anti-ischemic ATP-sensitive potassium channel (KATP) opener without vasorelaxation: N-(6-aminobenzopyranyl)-N‘-benzyl-N‘‘-cyanoguanidine analogue. J Med Chem. 2001;44(24):4207–4215.
   PubMed Web of Science ®Google Scholar
• Hu Z, Ou L, Li S, Yang L. Synthesis and biological evaluation of 1-cyano-2-amino-benzimidazole derivatives as a novel class of antitumor agents. Med Chem Res. 2014;23(6):3029–3038.
   Web of Science ®Google Scholar
• Li ZQ, Chen X, Wang Y. Small molecules targeting ubiquitination to control inflammatory diseases. Drug Discov Today. 2021;26(10):2414–2422.
   PubMed Web of Science ®Google Scholar
• Kim KY, Kim BG, Kim S-O, Yoo S-E, Kwak Y-G, Chae S-W, Hong KW. Prevention of lipopolysaccharide-induced apoptosis by (2S,3S,4R)-N"-cyano-N-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N′-benzylguanidine, a benzopyran analog. J Pharmacol Exp Ther. 2002;300(2):535–542.
   PubMed Web of Science ®Google Scholar
• Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Shewchuk LM, Tavares FX, Willard DH, Wright LL. Novel and potent cyclic cyanamide-based cathepsin K inhibitors. Bioorg Med Chem Lett. 2005;15(7):1815–1819.
   PubMed Web of Science ®Google Scholar
• (a) Lainé D, Palovich M, McCleland B, Petitjean E, Delhom I, Xie H, Deng J, Lin G, Davis R, Jolit A, et al. Discovery of novel cyanamide-based inhibitors of cathepsin C. ACS Med Chem Lett. 2011;2(2):142–147;
   PubMed Web of Science ®Google Scholar
  (b) Falgueyret JP, Oballa RM, Okamoto O, Wesolowski G, Aubin Y, Rydzewski RM, Prasit P, Riendeau D, Rodan SB, Percival MD, et al. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. J Med Chem. 2001;44(1):94–104.
   PubMed Web of Science ®Google Scholar
• Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, Marchand F, Dehvari M, Wotherspoon G, Winter J, Ullah J, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci USA. 2007;104(25):10655–10660.
   PubMed Web of Science ®Google Scholar
• Montague-Cardoso K, Malcangio M. Cathepsin S as a potential therapeutic target for chronic pain. Med Drug Discov. 2020;7:100047.
   PubMedGoogle Scholar
• (a) Tars K, Vullo D, Kazaks A, Leitans J, Lends A, Grandane A, Zalubovskis R, Scozzafava A, Supuran CT. Sulfocoumarins (1, 2-benzoxathiine-2, 2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. J Med Chem. 2013;56(1):293–300;
   PubMed Web of Science ®Google Scholar
  (b) Leitans J, Kazaks A, Balode A, Ivanova J, Zalubovskis R, Supuran CT, Tars K. Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX. J Med Chem. 2015;58(22):9004–9009;
   PubMed Web of Science ®Google Scholar
  (c) Grandane A, Tanc M, Di Cesare Mannelli L, Carta F, Ghelardini C, Žalubovskis R, Supuran CT. 6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells. J Med Chem. 2015;58(9):3975–3983;
   PubMed Web of Science ®Google Scholar
  (d) Grandāne A, Nocentini A, Domračeva I, Žalubovskis R, Supuran CT. Development of oxathiino [6, 5-b] pyridine 2, 2-dioxide derivatives as selective inhibitors of tumor-related carbonic anhydrases IX and XII. Eur J Med Chem. 2020;200:112300;
   PubMed Web of Science ®Google Scholar
  (e) Abdoli M, Angeli A, Bozdag M, Carta F, Kakanejadifard A, Saeidian H, Supuran CT. Synthesis and carbonic anhydrase I, II, VII, and IX inhibition studies with a series of benzo [d] thiazole-5-and 6-sulfonamides. J Enzyme Inhib Med Chem. 2017;32(1):1071–1078;
   PubMed Web of Science ®Google Scholar
  (f) Abdoli M, Bozdag M, Angeli A, Supuran C. Benzamide-4-sulfonamides are effective human carbonic anhydrase I, II, VII, and IX inhibitors. Metabolites. 2018;8(2):37;
   PubMed Web of Science ®Google Scholar
  (g) Abdoli M, Giovannuzzi S, Supuran CT, Žalubovskis R. 4-(3-Alkyl/benzyl-guanidino) benzenesulfonamides as selective carbonic anhydrase VII inhibitors. J Enzyme Inhib Med Chem. 2022;37(1):1568–1576.
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem. 1971;246(8):2561–2573.
   PubMed Web of Science ®Google Scholar
• (a) Pastorekova S, Casini A, Scozzafava A, Vullo D, Pastorek J, Supuran CT. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004;14(4):869–873;
   PubMed Web of Science ®Google Scholar
  (b) Vullo D, Voipio J, Innocenti A, Rivera C, Ranki H, Scozzafava A, Kaila K, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2005;15(4):971–976;
   PubMed Web of Science ®Google Scholar
  (c) Gieling RG, Babur M, Mamnani L, Burrows N, Telfer BA, Carta F, Winum J-Y, Scozzafava A, Supuran CT, Williams KJ, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem. 2012;55(11):5591–5600;
   PubMed Web of Science ®Google Scholar
  (d) Grandane A, Nocentini A, Werner T, Zalubovskis R, Supuran CT. Benzoxepinones: a new isoform-selective class of tumor associated carbonic anhydrase inhibitors. Bioorg Med Chem. 2020;28(11):115496.
   PubMed Web of Science ®Google Scholar
• (a) Krasavin M, Sharonova T, Sharoyko V, Zhukovsky D, Kalinin S, Žalubovskis R, Tennikova T, Supuran CT. Combining carbonic anhydrase and thioredoxin reductase inhibitory motifs within a single molecule dramatically increases its cytotoxicity. J Enzyme Inhib Med Chem. 2020;35(1):665–671;
   PubMed Web of Science ®Google Scholar
  (b) Ivanova J, Balode A, Žalubovskis R, Leitans J, Kazaks A, Vullo D, Tars K, Supuran CT. 5-Substituted-benzylsulfanyl-thiophene-2-sulfonamides with effective carbonic anhydrase inhibitory activity: Solution and crystallographic investigations. Bioorg Med Chem. 2017;25(3):857–863;
   PubMed Web of Science ®Google Scholar
  (c) Alterio V, Tanc M, Ivanova J, Zalubovskis R, Vozny I, Monti SM, Di Fiore A, De Simone G, Supuran CT. X-ray crystallographic and kinetic investigations of 6-sulfamoyl-saccharin as a carbonic anhydrase inhibitor. Org Biomol Chem. 2015; 13(13):4064–4069.
   PubMed Web of Science ®Google Scholar
• (a) Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases. Curr Top Med Chem. 2007;7(9):901–908;
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT, Clare BW. Carbonic anhydrase inhibitors. Part 57. Quantum chemical QSAR of a group of 1,3,4-thiadiazole and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties. Eur J Med Chem. 1999;34(1):41–50;
   Web of Science ®Google Scholar
  (c) Supuran CT, Barboiu M, Luca C, Pop E, Brewster ME, Dinculescu A. Carbonic anhydrase activators. Part 14. Synthesis of mono- and bis- pyridinium salt derivatives of 2-amino-5-(2-aminoethyl)- and 2-amino-5-(3-aminopropyl)-1,3,4-thiadiazole, and their interaction with isozyme II. Eur J Med Chem. 1996;31(7-8):597–606;
   Web of Science ®Google Scholar
  (d) Aspatwar A, Barker H, Aisala H, Zueva K, Kuuslahti M, Tolvanen M, Primmer CR, Lumme J, Bonardi A, Tripathi A, et al. Cloning, purification, kinetic and anion inhibition studies of a recombinant β-carbonic anhydrase from the Atlantic salmon parasite platyhelminth Gyrodactylus salaris. J Enzyme Inhib Med Chem. 2022;37(1):1577–1586.
   PubMed Web of Science ®Google Scholar
• (a) Urbanski LJ, Vullo D, Parkkila S, Supuran CT. An anion and small molecule inhibition study of the β-carbonic anhydrase from Staphylococcus aureus. J Enzyme Inhib Med Chem. 2021;36(1):1088–1092;
   PubMed Web of Science ®Google Scholar
  (b) Urbanski LJ, Bua S, Angeli A, Kuuslahti M, Hytönen VP, Supuran CT, Parkkila S. Sulphonamide inhibition profile of Staphylococcus aureus β-carbonic anhydrase. J Enzyme Inhib Med Chem. 2020;35(1):1834–1839.
   PubMed Web of Science ®Google Scholar
• (a) Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Supuran CT. Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates. Bioorg Med Chem. 2011;19(16):5023–5030;
   PubMed Web of Science ®Google Scholar
  (b) Vullo D, Nishimori I, Minakuchi T, Scozzafava A, Supuran CT. Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium. Bioorg Med Chem Lett. 2011;21(12):3591–3595;
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol. 2011;2:34.
   PubMed Web of Science ®Google Scholar
• (a) De Simone G, Di Fiore A, Truppo E, Langella E, Vullo D, Supuran CT, Monti SM. Exploration of the residues modulating the catalytic features of human carbonic anhydrase XIII by a site-specific mutagenesis approach. J Enzyme Inhib Med Chem. 2019;34(1):1506–1510;
   PubMed Web of Science ®Google Scholar
  (b) Monti DM, De Simone G, Langella E, Supuran CT, Di Fiore A, Monti SM. Insights into the role of reactive sulfhydryl groups of carbonic anhydrase III and VII during oxidative damage. J Enzyme Inhib Med Chem. 2017;32(1):5–12.
   PubMed Web of Science ®Google Scholar
• (a) Gramoli JL, Wilkinson BJ. Characterization and identification of coagulase-negative, heat-stable deoxyribonuclease-positive Staphylococci. J Gen Microbiol. 1978;105(2):275–285;
   PubMedGoogle Scholar
  (b) Fungwithaya P, Boonchuay K, Narinthorn R, Sontigun N, Sansamur C, Petcharat Y, Thomrongsuwannakij T, Wongtawan T. First study on diversity and antimicrobial-resistant profile of Staphylococci in sports animals of Southern Thailand. Vet World. 2022;15(3):765–774;
   PubMed Web of Science ®Google Scholar
  (c) Cai Y, Zheng L, Lu Y, Zhao X, Sun Y, Tang X, Xiao J, Wang C, Tong C, Zhao L, et al. Inducible resistance to β-lactams in oxacillin-susceptible mecA1-positive Staphylococcus sciuri isolated from retail pork. Front Microbiol. 2021; 12:721426;
   PubMed Web of Science ®Google Scholar
  (d) Chen S, Wang Y, Chen F, Yang H, Gan M, Zheng SJ. A highly pathogenic strain of Staphylococcus sciuri caused fatal exudative epidermitis in piglets. PLoS One. 2007;2(1):e147.
   PubMed Web of Science ®Google Scholar
• Madhaiyan M, Wirth JS, Saravanan VS. Phylogenomic analyses of the Staphylococcaceae family suggest the reclassification of five species within the genus Staphylococcus as heterotypic synonyms, the promotion of five subspecies to novel species, the taxonomic reassignment of five Staphylococcus species to Mammaliicoccus gen. nov., and the formal assignment of Nosocomiicoccus to the family Staphylococcaceae. Int J Syst Evol Microbiol. 2020;70(11):5926–5936.
   PubMed Web of Science ®Google Scholar
• Angeli A, Urbański LJ, Capasso C, Parkkila S, Supuran CT. Activation studies with amino acids and amines of a β-carbonic anhydrase from Mammaliicoccus (Staphylococcus) sciuri previously annotated as Staphylococcus aureus (SauBCA) carbonic anhydrase. J Enzyme Inhib Med Chem. 2022;37(1):2786–2792.
   PubMed Web of Science ®Google Scholar